Share This Page
ECONOPRED Drug Patent Profile
✉ Email this page to a colleague
When do Econopred patents expire, and what generic alternatives are available?
Econopred is a drug marketed by Harrow Eye and is included in one NDA.
The generic ingredient in ECONOPRED is prednisolone acetate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Econopred
A generic version of ECONOPRED was approved as prednisolone acetate by LUPIN on August 2nd, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ECONOPRED?
- What are the global sales for ECONOPRED?
- What is Average Wholesale Price for ECONOPRED?
Summary for ECONOPRED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,407 |
| DailyMed Link: | ECONOPRED at DailyMed |
Recent Clinical Trials for ECONOPRED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oregon Health and Science University | Phase 4 |
| University of California, San Francisco | Phase 4 |
| Winston Chamberlain, MD, PhD | Phase 4 |
US Patents and Regulatory Information for ECONOPRED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | ECONOPRED | prednisolone acetate | SUSPENSION/DROPS;OPHTHALMIC | 017468-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
ECONOPRED Market Dynamics, Revenue Outlook, Generic Competition, and Patent Position
Econopred is a legacy ophthalmic corticosteroid brand based on prednisolone acetate. Its commercial position is now driven by generic substitution, contracting, pharmacy availability, and ophthalmology prescribing habits rather than patent exclusivity. Public filings do not disclose standalone Econopred revenue, and the brand does not appear to have a material independent financial contribution to Alcon’s current portfolio.
What is Econopred and how is it used?
Econopred is a prescription ophthalmic corticosteroid used to reduce inflammation in the eye. The Econopred product family historically included:
| Product | Active ingredient | Dosage form | Typical strength | Therapeutic role |
|---|---|---|---|---|
| Econopred | Prednisolone acetate | Ophthalmic suspension | 0.12% | Mild-to-moderate ocular inflammation |
| Econopred Plus | Prednisolone acetate | Ophthalmic suspension | 1% | More intensive ocular inflammation |
| Generic equivalents | Prednisolone acetate | Ophthalmic suspension | 0.12% and 1% | Broad substitution market |
The product requires shaking before use because prednisolone acetate is a suspension. The FDA-approved labeling identifies risks associated with topical ophthalmic corticosteroids, including elevated intraocular pressure, glaucoma, delayed wound healing, cataract formation, and secondary infection. Long-term use requires ophthalmic monitoring. [1]
Prednisolone acetate remains clinically relevant in postoperative inflammation, anterior uveitis, and other inflammatory eye conditions. Econopred competes with generic prednisolone acetate and branded products such as Pred Forte, Omnipred, and other corticosteroid formulations.
What is the current FDA regulatory status of Econopred?
Econopred is a prescription ophthalmic drug regulated through the FDA’s new drug application and abbreviated new drug application systems. The commercial market now includes multiple generic prednisolone acetate products approved under ANDAs.
FDA regulatory status is more commercially important for the generic products than for the legacy brand. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for ophthalmic suspensions. The active ingredient, concentration, dosage form, route of administration, and labeling determine substitutability.
The FDA’s Orange Book is the controlling public source for listed products, therapeutic-equivalence codes, patent information, and marketing-status designations. [2] Product availability can change because of discontinuation, supply decisions, manufacturing issues, or corporate portfolio rationalization. A historical brand name does not establish current commercial availability.
What is the Orange Book status of Econopred?
Econopred’s economic value is limited by the absence of a meaningful current exclusivity barrier. Prednisolone acetate ophthalmic suspension is an established multisource product. Generic versions have been marketed for years, and the core composition is not an effective basis for new market exclusivity.
No active, commercially significant Orange Book exclusivity position is generally associated with the legacy Econopred brand. The relevant competitive question is whether a specific marketed product remains listed and available, not whether the Econopred name retains historical FDA recognition.
When did Econopred lose exclusivity?
Econopred’s core market protection expired long before the current genericized ophthalmic corticosteroid market developed. The product is not comparable to a recently launched drug with a defined five-year NCE period, three-year clinical-investigation exclusivity, or pediatric extension.
The commercial exclusivity timeline is therefore best understood as follows:
| Period | Market condition | Financial effect |
|---|---|---|
| Initial commercialization | Branded prednisolone acetate ophthalmic product | Brand pricing and physician familiarity |
| Generic entry period | ANDA-approved prednisolone acetate products enter | Price erosion and substitution |
| Mature generic market | Multiple suppliers and pharmacy substitution | Low unit pricing and fragmented share |
| Current market | Brand recognition persists, but generic supply dominates | Limited standalone brand revenue |
The lack of a current patent moat means that any remaining Econopred value comes from brand recognition, prescriber familiarity, channel relationships, and product availability.
How many patents protect Econopred?
The commercially relevant answer is that no meaningful active patent estate appears to protect the core Econopred product today.
What patents protect prednisolone acetate ophthalmic suspension?
The original product concept is based on an old corticosteroid active ingredient and a conventional ophthalmic suspension. Core composition and basic use patents are not expected to block modern generic entry. Any historical patents associated with the original product or formulation would have expired, been rendered commercially irrelevant, or been overtaken by generic approvals.
Potentially protectable subject matter in this category includes:
- Suspension particle-size control
- Preservative systems
- Container-closure systems
- Drop-delivery devices
- Stabilization methods
- Combination products
- New dosing regimens
- Specialized manufacturing processes
These features could support later patents for a particular product, but they do not automatically protect Econopred or prevent generic prednisolone acetate products from entering.
Are there Paragraph IV challenges to Econopred?
Paragraph IV litigation is not the central market issue for Econopred. The product is a legacy branded ophthalmic corticosteroid, and generic prednisolone acetate products have already established market access.
A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For a mature product with no commercially meaningful active patent estate, generic competition usually proceeds through ordinary ANDA pathways rather than high-value patent litigation.
No major current Paragraph IV dispute is publicly associated with Econopred as a standalone commercial franchise. Litigation risk is more relevant to newer ophthalmic products with device, formulation, or combination-product patents.
What generic competition affects Econopred?
Generic prednisolone acetate ophthalmic suspension is the primary competitive force. Products compete on:
- Wholesale acquisition cost and payer reimbursement.
- Pharmacy inventory and substitution.
- Bottle size and packaging.
- Drop consistency and suspension performance.
- Prescriber confidence.
- Supply reliability.
- Manufacturer contracts and distribution reach.
The market has low technological differentiation at the active-ingredient level. Suppliers can still differentiate through suspension quality, packaging, manufacturing reliability, and customer service.
Generic competition creates a structurally low-price market. Ophthalmic products have higher manufacturing and quality-control requirements than many oral solid products, but those requirements do not create a durable barrier when several manufacturers already possess the necessary capabilities.
What are the main market dynamics for Econopred?
Generic substitution is the dominant force
Prednisolone acetate ophthalmic suspension is a mature multisource product. Payers and pharmacies generally favor lower-cost generic alternatives. Brand retention is most likely where a physician specifically prescribes the branded product, a patient has prior experience with it, or supply problems affect a generic supplier.
The product remains clinically useful
The market is not disappearing because ocular inflammation remains common in ophthalmology. Cataract surgery, corneal procedures, uveitis, and other inflammatory conditions sustain demand for topical corticosteroids.
The commercial issue is price capture. Clinical demand can remain stable while brand revenue declines because generic products absorb prescription volume.
Ophthalmic manufacturing creates operational risk
Sterility, particulate control, viscosity, uniformity, container integrity, and drop-delivery performance affect product quality. Manufacturing interruptions can produce temporary shortages or share shifts. These operational factors may matter more than patent rights in the current Econopred market.
Substitution is clinically constrained but commercially powerful
Prednisolone acetate is not interchangeable in every clinical situation with other topical steroids. Difluprednate, loteprednol, dexamethasone, fluorometholone, and prednisolone sodium phosphate have different potency, formulation, tolerability, and clinical-use profiles.
Within the prednisolone acetate category, however, therapeutic substitution is comparatively strong. Physicians may switch suppliers when the active ingredient, strength, dosage form, and labeling are equivalent.
How does Econopred compare with competing ophthalmic corticosteroids?
| Product or category | Active ingredient | Commercial position | Main competitive advantage |
|---|---|---|---|
| Econopred / generic equivalents | Prednisolone acetate | Mature, genericized | Familiarity and broad clinical use |
| Pred Forte | Prednisolone acetate | Branded legacy competitor | Brand recognition and prescriber history |
| Omnipred | Prednisolone acetate | Branded or legacy market position | Established ophthalmic brand |
| Lotemax | Loteprednol etabonate | Differentiated branded steroid | Lower perceived steroid-related risk in selected uses |
| Durezol | Difluprednate | Higher-potency branded product | Potency and dosing profile |
| Maxidex and equivalents | Dexamethasone | Alternative corticosteroid | Established active ingredient and formulations |
| Fluorometholone products | Fluorometholone | Lower-potency alternative | Use in selected inflammation settings |
Econopred’s strongest competitive position is in the established prednisolone acetate category. Its weakest position is against differentiated products that justify premium pricing through formulation, potency, tolerability, or dosing convenience.
What is the revenue exposure of Econopred?
No public Alcon filing reports Econopred revenue as a separate product line. Alcon reports results by operating segment, including Surgical and Vision Care, rather than disclosing financial performance for individual legacy ophthalmic brands. [3]
The likely financial profile is:
| Financial indicator | Assessment |
|---|---|
| Standalone revenue disclosure | Not publicly reported |
| Revenue growth potential | Low |
| Price trend | Downward or flat under generic pressure |
| Volume trend | Stable clinical demand, but brand share is vulnerable |
| Gross-margin outlook | Constrained by generic competition |
| Patent-driven pricing power | Minimal |
| Strategic value | Portfolio continuity and ophthalmic brand recognition |
| Materiality to Alcon | Unlikely to be significant relative to major franchises |
Econopred should therefore be modeled as a mature, low-growth ophthalmic product rather than a growth asset. Revenue estimates based on the entire prednisolone acetate market would overstate Econopred’s brand exposure because generic manufacturers capture much of the category.
What generic launch scenarios exist for Econopred?
Base case: continued generic dominance
Generic prednisolone acetate maintains most prescription volume. The brand remains available in selected channels but has limited pricing power. Revenue declines gradually or remains small and stable.
Upside case: supply disruption among generic manufacturers
A shortage, recall, or manufacturing interruption could temporarily increase demand for branded or alternative suppliers. This would likely produce a short-lived volume benefit rather than a durable change in market structure.
Downside case: brand withdrawal or channel contraction
If the manufacturer reduces distribution, discontinues the product, or prioritizes newer ophthalmic products, remaining demand would migrate to generic prednisolone acetate or competing corticosteroids.
Product-defense case: differentiated reformulation
A new delivery system, preservative-free formulation, or improved suspension could support premium pricing if it obtained regulatory approval and demonstrated a meaningful clinical or convenience benefit. That would be a new product strategy, not a continuation of Econopred’s legacy exclusivity.
What licensing deals and settlements affect Econopred?
No major current licensing transaction or settlement is publicly associated with Econopred as a distinct asset. The product is too mature for licensing economics based on patent exclusivity.
Commercial arrangements in this category are more likely to involve:
- Contract manufacturing
- Wholesale and pharmacy distribution
- Generic supply agreements
- Portfolio divestitures
- Product-rights transfers
- Manufacturing-site changes
Settlement agreements are more relevant to branded ophthalmic products with active formulation or device patents. Econopred’s mature generic status reduces the probability that a new settlement would materially change its competitive outlook.
What manufacturing and intellectual-property barriers remain?
The principal barriers are regulatory and operational rather than patent-based.
Manufacturing barriers
Manufacturers must control:
- Sterility assurance
- Particle size and sedimentation
- Redispersibility after shaking
- Uniform dose delivery
- Preservative performance
- Container-closure integrity
- Stability throughout shelf life
These requirements can limit the number of reliable suppliers, but they do not create durable exclusivity once several approved manufacturers are active.
Intellectual-property barriers
A future supplier could pursue patents covering a specific:
- Preservative-free container
- Multidose delivery system
- Suspension-stabilization method
- Particle-size distribution
- Combination therapy
- Dosing regimen
Such patents would protect the claimed improvement, not the broad use of prednisolone acetate ophthalmic suspension.
How strong is the Econopred patent estate?
The patent estate is weak from a current commercial perspective.
| Factor | Rating | Rationale |
|---|---|---|
| Core active ingredient protection | Weak | Prednisolone acetate is an established compound |
| Core formulation protection | Weak | Multiple generic formulations exist |
| Orange Book leverage | Limited | No meaningful current exclusivity position |
| Device protection | Product-specific | No broad Econopred barrier identified |
| Litigation leverage | Low | Genericized market and mature product |
| Manufacturing know-how | Moderate operational value | Sterile suspension production requires controls |
| Brand value | Limited but persistent | Familiarity may support residual demand |
Key Takeaways
- Econopred is a legacy prednisolone acetate ophthalmic corticosteroid brand.
- Generic prednisolone acetate is the primary commercial competitor.
- The product has no meaningful current patent-driven pricing power.
- Public filings do not disclose standalone Econopred revenue.
- Market demand remains clinically durable, but brand revenue is structurally constrained.
- Manufacturing quality, supply reliability, and distribution matter more than patent exclusivity.
- Paragraph IV litigation, biosimilar risk, and major settlement exposure are not central to Econopred.
- A differentiated reformulation could create new value, but the legacy product itself is a mature low-growth asset.
FAQs
Is Econopred still available in the United States?
Availability depends on the specific Econopred product, manufacturer, and distribution channel. Generic prednisolone acetate ophthalmic suspension is broadly established and is the principal source of supply.
Is Econopred the same as Pred Forte?
Both products are associated with prednisolone acetate ophthalmic suspension, particularly at the 1% strength. Exact product equivalence depends on strength, formulation, manufacturer, labeling, and FDA therapeutic-equivalence status.
Can pharmacies substitute generic prednisolone acetate for Econopred?
Substitution depends on the prescribed strength, dosage form, state law, prescriber instructions, and the FDA therapeutic-equivalence designation for the specific generic product.
Does Econopred have biosimilar competition?
No. Econopred is a small-molecule ophthalmic drug, not a biologic. Its competitive threat comes from generic drugs approved through the ANDA pathway, not biosimilars.
What would increase the commercial value of Econopred?
A preservative-free presentation, improved delivery system, stronger supply reliability, or a clinically differentiated formulation could increase value. Those improvements would require separate regulatory and intellectual-property strategies.
References
- U.S. Food and Drug Administration. (n.d.). Econopred and Econopred Plus prescribing information. FDA labeling database.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.
- Alcon Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
More… ↓
